A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573 · clinicaltrials.gov ↗

RECRUITING

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Epidermolysis Bullosa, Dystrophic
Epidermolysis Bullosa, Junctional

Interventions

DRUG: Filsuvez

Sponsor

Amryt Pharma

Collaborators

[object Object]